# Relay Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/relay-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.relaytx.com
- Total disclosed funding: $519M
- Latest round: Series C (Dec 18, 2018)
- Investors on record: 11

## About

Based in Massachusetts, US, and founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson, Relay Therapeutics, Inc. provides an allosteric drug-discovery platform that intends to apply computational techniques to protein motion. In 2018, Relay Therapeutics, Inc. raised USD 400 million in a Series C funding, led by SB Investment Advisers, with participation from Foresite Capital, Perceptive Advisors, Tavistock Group, Alexandria Venture Investments, BVF Partners, Casdin Capital, EcoR1 Capital, and GV. In July 2020, Relay Therapeutics, Inc. raised USD 400 million in an IPO, selling 20 million shares at USD 20 per share. The company is listed on Nasdaq under the ticker symbol RLAY. As of October 2021, Sanjiv K. Patel is the CEO and President of Relay Therapeutics, Inc. and employs approximately 232 people.

Relay Therapeutics, Inc. provides Relay Therapeutics’ Dynamo™ platform that integrates leading computation and experimental approaches to target drug-protein that have previously been intractable. The company develops oncology therapeutics through an allosteric drug-discovery platform. It works to improve small molecule therapeutic discovery in targeted cancer, with an initial focus on improving the drug discovery process. The platform uses computational methods and experimental approaches to discover proteins' motion and function inside human cells to treat patients with cancer. Its products include RLY-1971, RLY-4008, and RLY-PI3K1047, a compound that targets cancer-associated mutant variants.

The company generated total revenue of USD 246.2 million for the first three quarters of 2021. In the fiscal year 2020, the company generated USD 82.654 million in revenue.

## Funding rounds

- Series C, Dec 18, 2018, $400M — Alexandria Venture Investments, GV, Tavistock Group, Foresite Capital, Casdin Capital, BVF Partners, EcoR1 Capital, Perceptive Advisors, SB Investment Advisers
- Series B, Dec 8, 2017, $63M — Alexandria Venture Investments, Third Rock Ventures, GV, Casdin Capital, BVF Partners, EcoR1 Capital, Section 32
- Series A, Sep 14, 2016, $56M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B, Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B, Series C
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C